TY - JOUR
T1 - Psychiatric genomics
T2 - An update and an Agenda
AU - Psychiatric Genomics Consortium Coordinating Committee
AU - Sullivan, Patrick F.
AU - Agrawal, Arpana
AU - Bulik, Cynthia M.
AU - Andreassen, Ole A.
AU - Børglum, Anders D.
AU - Breen, Gerome
AU - Cichon, Sven
AU - Edenberg, Howard J.
AU - Faraone, Stephen V.
AU - Gelernter, Joel
AU - Mathews, Carol A.
AU - Nievergelt, Caroline M.
AU - Smoller, Jordan W.
AU - O’Donovan, Michael C.
AU - Daly, Mark
AU - Gill, Michael
AU - Kelsoe, John
AU - Koenen, Karestan
AU - Levinson, Douglas
AU - Lewis, Cathryn
AU - Neale, Ben
AU - Posthuma, Danielle
AU - Sebat, Jonathan
AU - Sklar, Pamela
N1 - Funding Information:
Dr. Sullivan is a scientific advisor for Pfizer and Lundbeck and received an honorarium from F. Hoffmann–La Roche. Dr. Bulik is a consultant for and grant recipient from Shire and is a member of its Scientific Advisory Board; she also receives royalties from Pearson and from Walker. Dr. Andreassen received a speaker’s honorarium from Lundbeck in 2016 and has received research grants from the Research Council of Norway. Dr. Børglum has received research grants from the Lundbeck Foundation supporting the Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH (grants R102-A9118 and R155-2014-1724). Dr. Breen has received speaking fees from Illumina and grant funding from Eli Lilly. Dr. Cichon is principal investigator on an investigator-initiated study with Actelion Pharmaceuticals (project title: NGS-based detection of rare mutations in NPC1 and NPC2 genes in patients with schizophrenia). In the past year, Dr. Faraone received income, potential income, travel expenses, continuing education support, and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind, and NeuroLifeSciences; with his institution, he holds U.S. patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD; in previous years, he received support from Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly; he receives royalties from books published by Guilford Press (Straight Talk About Your Child’s Mental Health), Oxford University Press (Schizophrenia: The Facts), and Elsevier (ADHD: Non-Pharmacologic Interventions); and he is principal investigator with ADHD in Adults (www.adhdinadults.com). Cardiff University received an honorarium from F. Hoffmann–La Roche for a presentation by Dr. O’Donovan in 2015. Multiple drug companies work with the Psychiatric Genomics Consortium in a manner equivalent to that of academic investigators. The other authors report no relationships with commercial interests. Received March 9, 2017; revision received May 8, 2017; accepted May 15, 2017; published online October 3, 2017.
Funding Information:
The Psychiatric Genomics Consortium (PGC) has received major funding from the National Institute of Mental Health and the National Institute on Drug Abuse (PGC3: U01 MH109528 and U01 MH109532, PGC2: U01 MH094421, PGC1: U01 MH085520). Dr. Agrawal is also supported by grant K02 DA32573 from the National Institute on Drug Abuse. Other significant funders include the Lundbeck Foundation, Stanley Center of the Broad Institute, Science Foundation Ireland, Cohen Veterans Bioscience, Norwegian Institute of Health, and Klarman Family Foundation. Dr. Faraone is supported by the K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway; the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement 602805; the European Union’s Horizon 2020 research and innovation program under grant agreement 667302; and NIMH grants 5R01MH101519 and U01 MH109536-01.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. This global effort is dedicated to rapid progress and open science, and in the past decade it has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders. The PGC has recently commenced a program of research designed to deliver “actionable” findings—genomic results that 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. The central idea of the PGC is to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework.
AB - The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. This global effort is dedicated to rapid progress and open science, and in the past decade it has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders. The PGC has recently commenced a program of research designed to deliver “actionable” findings—genomic results that 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. The central idea of the PGC is to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework.
UR - http://www.scopus.com/inward/record.url?scp=85040315988&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2017.17030283
DO - 10.1176/appi.ajp.2017.17030283
M3 - Article
C2 - 28969442
AN - SCOPUS:85040315988
VL - 175
SP - 15
EP - 27
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
SN - 0002-953X
IS - 1
ER -